10.01.08
Indication: Upper respiratory tract infections (URTIs or URIs); safety and tolerability of formulation
Source: Pediatrics, August 2008; 122(2):e402-10.
Research: A randomized, double-blind, placebo-controlled Canadian trial was conducted to measure the safety and tolerability of Cold-fX in children. Seventy-five children aged 3 to 12 years were recruited for the winter of 2005-2006. Forty-six of these children developed an upper respiratory infection, so within 48 hours of onset they were randomly given either a placebo or American ginseng at two different dosage levels for three days.
Results: There were no serious adverse events reported and the ginseng was well tolerated. FDA and Health Canada are investigating the safety and efficacy of children’s cold remedies. The researchers believe the safety and tolerability of North American ginseng merits additional evaluation in the treatment of URTIs in children.
Source: Pediatrics, August 2008; 122(2):e402-10.
Research: A randomized, double-blind, placebo-controlled Canadian trial was conducted to measure the safety and tolerability of Cold-fX in children. Seventy-five children aged 3 to 12 years were recruited for the winter of 2005-2006. Forty-six of these children developed an upper respiratory infection, so within 48 hours of onset they were randomly given either a placebo or American ginseng at two different dosage levels for three days.
Results: There were no serious adverse events reported and the ginseng was well tolerated. FDA and Health Canada are investigating the safety and efficacy of children’s cold remedies. The researchers believe the safety and tolerability of North American ginseng merits additional evaluation in the treatment of URTIs in children.